Physician profile
Daniel D Carroll
NPI 1467428987
$4,574.39
in general payments reported to CMS, 2019-2025
37 companies · $371 in 2025
The $371 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $530 · 2021: $946 · 2022: $1,053 · 2023: $662 · 2024: $529 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,146.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,072.28 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Glaxosmithkline, LLC. | $331.73 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $316.21 | 2019-2025 | |
| Lilly USA, LLC | $223.32 | 2019-2025 | Mounjaro, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $214.30 | 2019-2024 | Eliquis, Camzyos |
| Astellas Pharma US INC | $155.28 | 2019-2024 | Veozah |
| Esperion Therapeutics, INC. | $154.69 | 2020-2023 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.76 | 2021-2024 | Synjardy, Jardiance |
| Amgen INC. | $93.61 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $84.93 | 2020-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.40 | 2021-2022 | |
| Horizon Therapeutics Plc | $45.70 | 2019-2022 | |
| Lundbeck LLC | $43.90 | 2022-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $39.45 | 2019-2023 | Breztri |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Carroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.